Showing 51-60 of 9243 results for "".
- ASA Lauds Three Honorees at Spring Galahttps://practicaldermatology.com/news/asa-lauds-three-honorees-at-spring-gala/2458602/The American Skin Association (ASA) honored Yale Educator Irwin M. Braverman, MD, Melanoma Researcher John M. Kirkwood MD and Nestlé’s SHIELD program at their Spring gala in New
- FDA Adds Bemotrizinol to OTC Sunscreen Monograph in First New UV Filter in Over 20 Yearshttps://practicaldermatology.com/news/fda-adds-bemotrizinol-to-otc-sunscreen-monograph-in-first-new-uv-filter-in-over-20-years/2487644/The US Food and Drug Administration (FDA) has finalized an administrative order adding bemotrizinol as a permitted active ingredient in over-the-counter (OTC) sunscreen products, marking the first addition of a new sunscreen active ingredient to the OTC sunscreen m
- Key Thickness Benchmark Identified for Thin Melanoma Death Riskhttps://practicaldermatology.com/news/key-thickness-benchmark-identified-thin-melanoma-death-risk/2470668/Melanomas with Breslow thickness between 0.8 and 1.0 mm are associated with nearly triple the risk of melanoma-related death compared to thinner melanomas, a new study of Australian registry data reports. "Most patients who present with primary cutaneous melanomas have thin tumors (≤ 1.0 m
- New Image-Guided Dermatology Therapy System Receives CE Mark in Europehttps://practicaldermatology.com/news/new-oncology-and-dermatology-device-approved-europe/2463232/Ultrasound tech manufacturer TOOsonix A/S announced that it has received EU Medical Device Regulation (MDR) CE certification for its image-guided dermatologic therapy system, System ONE-M™, according to a news release from the company. The device facilitates the treatment of common skin c
- Study: Image-Guided Superficial Radiation Therapy Yields Superior 2-Year Recurrence Rates Compared to Mohshttps://practicaldermatology.com/news/study-image-guided-superficial-radiation-therapy-yields-superior-2-year-recurrence-rates-compared-to-mohs/2462035/Image-guided superficial radiation therapy (Image-Guided SRT, or IGSRT), bested Mohs micrographic surgery (MMS) for individuals with early stage nonmelanoma skin cancers (NMSCs). The study, which is the first to directly compare two-year recurrence probabilities of image-guided SRT to M
- Pathologist Survey: Melanoma Is Overdiagnosedhttps://practicaldermatology.com/news/pathologist-survey-melanoma-is-overdiagnosed/2461180/Many pathologists agree that overdiagnosis of skin cancer happens, but don’t change diagnosis behavior, according to a new study. “Overdiagnosis is the diagnosis of disease that will not harm a person in their lifetime. If melanoma is being overdiagnosed, it means that too m
- Accure Acne Seeks to Raise Up To $20 Million Through Private Placement Offeringhttps://practicaldermatology.com/news/accure-acne-seeks-to-raise-up-to-20-million-through-private-placement-offering/2460776/Accure Acne, Inc. has launched a private placement offering on the M-Vest platform to raise up to $20 Million. Building on the research of R. Rox Anderson, MD, Accure Co-Founder and Chief Scientific & Medical Officer, Accure has developed the Accure Laser System, an&n
- Viper Equity Partners Seeks to Expand into Florida and Georgia Dermatology Marketshttps://practicaldermatology.com/news/viper-equity-partners-seeks-to-expand-into-florida-and-georgia-dermatology-markets/2460303/Viper Equity Partners is turning its attention to key dermatology and related aesthetics offices in Florida and Georgia to join private equity-backed partnerships. In an effort spearheaded by Senior Vice President Nina Das (see photo), the North Palm Beach-based M&A advisory firm is
- US FDA Grants Dupixent Priority Review for Moderate-to-Severe AD in Adolescentshttps://practicaldermatology.com/news/us-fda-grants-dupixent-priority-review-for-moderate-to-severe-ad-in-adolescents/2457517/The US Food and Drug Administration (FDA) has granted Priority Review for Dupixent (dupilumab) as a potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitis (AD). Currently, there are no FDA-approved systemic biologic medicines to treat adolescents with m
- Meet the Newest AAD Officers and Board Membershttps://practicaldermatology.com/news/meet-the-newest-aad-officers-and-board-members/2457876/Suzanne M. Olbricht, MD, FAAD, a Boston-based dermatologist, will take the helm of the American Academy of Dermatology (AAD) as the new President. Her one-year term officially begins on Tuesday, Feb. 20, at the conclusion of the 2018 AAD Annual Meeting in San Diego. Dr. Olbricht is an ass